凝血因子XIII:创伤中纤溶表型的未被认识调节因子——与半胱氨酸组织蛋白酶降解纤溶酶原的潜在联系
本研究基于快速血栓弹力图和tPA增强血栓弹力图将创伤患者血浆分为四种纤溶表型(纤溶亢进、纤溶低下、纤溶关闭和生理性纤溶),采用液相色谱-质谱联用蛋白质组学、FXIII浓度/活性检测和蛋白质印迹分析。结果发现纤溶关闭患者中四种已知可交联入纤维蛋白的蛋白水平存在差异,且纤溶关闭患者血浆FXIII活性显著高于其他表型。体外研究显示半胱氨酸组织蛋白酶可降解凝血和纤溶蛋白(包括纤溶酶原、tPA和纤维蛋白原),组织蛋白酶L暴露完全破坏离体纤维蛋白凝块形成并损害纤溶酶功能。作者认为FXIII活性升高和蛋白酶抑制剂掺入纤维蛋白凝块可能通过抑制半胱氨酸组织蛋白酶活性来调控创伤患者的纤溶关闭。
要点
- 纤溶关闭患者血浆FXIII活性显著高于其他纤溶表型患者。
- 纤溶关闭患者血浆中四种已知可交联入纤维蛋白的蛋白水平存在差异。
- 半胱氨酸组织蛋白酶在体外可降解纤溶酶原、tPA和纤维蛋白原。
- 组织蛋白酶L暴露完全破坏离体纤维蛋白凝块形成并损害纤溶酶功能。
- FXIII和半胱氨酸组织蛋白酶可能是创伤诱导性凝血病的可能Contributor,需进一步研究。
适用人群与场景
- 创伤患者血浆样本,按快速血栓弹力图和tPA增强血栓弹力图分为纤溶亢进、纤溶低下、纤溶关闭和生理性纤溶四种纤溶表型。
诊断标准与关键阈值
- 纤溶表型分类依据快速血栓弹力图和tPA增强血栓弹力图。
研究设计与关键结果
- 研究类型为实验室研究,使用创伤患者血浆样本进行蛋白质组学分析、FXIII浓度/活性检测和蛋白质印迹确认,并进行体外研究评估半胱氨酸组织蛋白酶介导的蛋白水解。
- 纤溶关闭患者血浆FXIII活性显著高于其他纤溶表型患者。
- 蛋白质组学分析发现纤溶关闭患者中四种已知可交联入纤维蛋白的蛋白水平存在差异。
- 半胱氨酸组织蛋白酶在体外降解凝血和纤溶蛋白,包括纤溶酶原、tPA和纤维蛋白原。
- 组织蛋白酶L暴露完全破坏离体纤维蛋白凝块形成并损害纤溶酶功能。
证据类型、等级与局限
- 证据类型:实验室研究(血浆蛋白质组学、FXIII活性检测、体外蛋白水解实验)。
- 作者结论:FXIII活性升高和蛋白酶抑制剂掺入纤维蛋白凝块可能通过抑制半胱氨酸组织蛋白酶活性来调控创伤患者的纤溶关闭;FXIII和半胱氨酸组织蛋白酶可能是创伤诱导性凝血病的可能Contributor,需进一步研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为FXIII和半胱氨酸组织蛋白酶可能是创伤诱导性凝血病的可能Contributor,需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Trauma-induced coagulopathy (TIC) has distinct fibrinolytic phenotypes based on viscoelastic testing. The underlying mechanisms behind differences in fibrinolytic responses to trauma are unclear. We hypothesized that plasma proteins crosslinked into fibrin clots by the transglutaminase activity of factor XIII (FXIII) may explain tissue-type plasminogen activator (tPA) responsiveness observed in fibrinolysis shutdown.
METHODS: Plasma samples from trauma patients were categorized into four fibrinolytic phenotypes (hyperfibrinolysis, hypofibrinolysis, fibrinolysis shutdown, and physiologic fibrinolysis) based on rapid thromboelastography and tPA-enhanced thromboelastography. Plasma underwent liquid chromatography-mass spectrometry proteomics for substrates of FXIII, evaluation for FXIII concentration/activity, and Western blotting to confirm proteomic findings. In vitro studies assessed cysteine cathepsin-mediated proteolysis of fibrinolytic and clot-related proteins.
RESULTS: Plasma proteomic analysis identified differences in levels of four proteins known to be crosslinked into fibrin in fibrinolysis shutdown patients. Patients with shutdown exhibited significantly higher plasma FXIII activity compared with other phenotypes. Because FXIII crosslinks protease inhibitors to fibrin, we studied inflammatory cysteine cathepsins' ability to degrade fibrinolytic proteins. Cysteine cathepsins degraded coagulation and fibrinolytic proteins in vitro, including plasminogen, tPA, and fibrinogen. Cathepsin L exposure completely disrupted ex vivo fibrin clot formation and impaired fibrinolytic enzyme function, highlighting its potential multifaceted role in TIC pathophysiology.
CONCLUSION: Elevated FXIII activity and protease inhibitor incorporation into fibrin clots may regulate fibrinolysis shutdown in trauma patients with fibrinolysis shutdown by inhibiting cysteine cathepsin activity. These findings identify FXIII and cysteine cathepsins as possible contributors to TIC that should be studied further.
参考来源
- Moore PK, Moore EE, Garner R, et al. Coagulation factor XIII: An unrecognized regulator of fibrinolytic phenotypes in trauma-A potential link to cysteine cathepsin degradation of plasminogen. J Trauma Acute Care Surg. 2025. PMID: 40712062. doi:10.1097/TA.0000000000004706
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。